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Abstract
Background: Mutations in LRRK2 are a common genetic cause of Parkinson’s disease (PD). LRRK2 interacts with
and phosphorylates a subset of Rab proteins including Rab8a, a protein which has been implicated in various
centrosome-related events. However, the cellular consequences of such phosphorylation remain elusive.
Methods: Human neuroblastoma SH-SY5Y cells stably expressing wildtype or pathogenic LRRK2 were used to test
for polarity defects in the context of centrosomal positioning. Centrosomal cohesion deficits were analyzed from
transiently transfected HEK293T cells, as well as from two distinct peripheral cell types derived from LRRK2-PD patients.
Kinase assays, coimmunoprecipitation and GTP binding/retention assays were used to address Rab8a phosphorylation
by LRRK2 and its effects in vitro. Transient transfections and siRNA experiments were performed to probe for the
implication of Rab8a and its phosphorylated form in the centrosomal deficits caused by pathogenic LRRK2.
Results: Here, we show that pathogenic LRRK2 causes deficits in centrosomal positioning with effects on neurite
outgrowth, cell polarization and directed migration. Pathogenic LRRK2 also causes deficits in centrosome cohesion
which can be detected in peripheral cells derived from LRRK2-PD patients as compared to healthy controls, and which
are reversed upon LRRK2 kinase inhibition. The centrosomal cohesion and polarity deficits can be mimicked when
co-expressing wildtype LRRK2 with wildtype but not phospho-deficient Rab8a. The centrosomal defects induced by
pathogenic LRRK2 are associated with a kinase activity-dependent increase in the centrosomal localization of
phosphorylated Rab8a, and are prominently reduced upon RNAi of Rab8a.
Conclusions: Our findings reveal a new function of LRRK2 mediated by Rab8a phosphorylation and related to various
centrosomal defects.
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Background
Mutations in the leucine-rich repeat kinase 2 (LRRK2)
gene cause familial Parkinson’s disease (PD) and varia-
tions around the LRRK2 locus increase risk for sporadic
PD, indicating that abnormal LRRK2 function contrib-
utes to disease pathogenesis [1, 2]. Various pathogenic
LRRK2 mutations have been described which all seem to
converge on causing increased phosphorylation of select
kinase substrates in intact cells [3], indicating that
LRRK2 kinase activity may represent a therapeutic PD
target. However, the downstream event(s) associated
with abnormal LRRK2-mediated substrate phosphoryl-
ation remain unknown.
LRRK2 has been reported to be involved in a number
of intracellular vesicular trafficking events [4–9] and also
plays an important role in neurite outgrowth/cell polar-
ity and cell migration [4, 10–14]. In dividing cells, patho-
genic LRRK2 is known to impair neuronal precursor cell
division in vitro and adult neurogenesis in vivo, deficits
which may at least in part contribute to some of the
age-dependent non-motor symptoms of PD patients
[15–18]. LRRK2 is also highly expressed in various non-
neuronal tissues, suggesting that it may play more general
cellular role(s) shared amongst distinct cell types. Whilst
displaying a broad subcellular distribution, LRRK2 can also
partially localize to a centrosomal compartment [19]. Inter-
estingly, a recent phosphoproteomics study has conclu-
sively identified a subset of Rab proteins including Rab8a
as LRRK2 kinase substrates [3]. Rab8a is a small GTPase
localized to various intracellular compartments including
Golgi, pericentrosomal recycling endosomes and centro-
somes, and is known to regulate centrosome-related events
[20–22]. However, the cellular consequences of LRRK2-
mediated Rab8a phosphorylation are currently unknown.
Proper centrosome positioning is important for main-
tenance of cell polarity and directed migration [23–25].
The centrosome also plays an important role during the
cell cycle, with centrosome duplication and separation
allowing for the formation of a bipolar spindle required
for appropriate chromosome segregation [26]. Finally,
the centrosome plays a crucial role for membrane traf-
ficking events to and from the pericentrosomal recyc-
ling endosome, and conversely, the pericentrosomal
recycling endosome can modulate centrosomal matur-
ation processes [20, 27], indicating that these two
compartments cooperate to regulate various key cellu-
lar processes.
In the present study, we report that pathogenic LRRK2
causes alterations in centrosome positioning which are
associated with deficits in neurite outgrowth and polar-
ized cell migration. In dividing cells, pathogenic LRRK2
causes centrosomal cohesion deficits which are also ob-
served in two distinct cell types derived from LRRK2-PD
patients as compared to healthy controls, and are reverted
by distinct LRRK2 kinase inhibitors. Furthermore, centro-
somal cohesion and polarity deficits are observed when co-
expressing wildtype LRRK2 along with wildtype but not
phospho-deficient Rab8a mutant, and are associated with a
kinase activity-dependent increase in the centrosomal accu-
mulation of phosphorylated Rab8a. Finally, the centrosomal
cohesion defects mediated by pathogenic LRRK2 are largely
abolished upon RNAi of Rab8a. Altogether, these data indi-
cate that pathogenic LRRK2 causes centrosomal alterations
via Rab8a phosphorylation.
Methods
Cell culture and transfections
SH-SY5Y cells stably expressing GFP, flag-tagged wild-
type LRRK2, or flag-tagged G2019S-mutant LRRK2 were
cultured as described [28, 29]. Briefly, cells were grown
in full medium (Dulbecco’s modified Eagle’s medium
containing high glucose and 15% fetal bovine serum,
non-essential amino acids, 50 μg/ml gentamycin (Life
Technologies) and 200 μg/ml hygromycin B (Invivogen),
and subcultured at a ratio of 1:6 twice a week. Transfec-
tion of cells was carried out at 80% confluence with
0.4 μg DNA and 1.5 μl Lipofectamine 2000 (Invitrogen)
per well of a 24-well plate in 200 μl OptiMEM. Five h
later, cells were changed into full medium, and passaged
the following day at a ratio of 1:5 onto coverslips,
followed by fixation and staining 72 h after transfection.
For differentiation, 10,000 cells were plated onto cover-
slips in 24-well plates and grown in full medium for
24 h to allow for proper attachment. Cells were then
changed to medium containing 3% fetal bovine serum
and 10 μM retinoic acid (Sigma), and differentiated dur-
ing 5 days, with medium changed every 48 h.
HEK293T cells were cultured as described [5, 8] and
transfected at 80% confluence with 2 μg of LRRK2 con-
structs (and 200 ng of Rab constructs where indicated)
and 6 μl of LipoD293 (SignaGen Laboratories) per well of
a 6 well plate for 5 h in full medium. Cells were split to
20% confluence the following day, and processed for im-
munocytochemistry or Western blot analysis 24 h later.
HELA cells were cultured as previously described [8],
Cells were plated in six-well plates at 40% confluence,
and transfected the following day with 400 ng of GFP-
tagged Rab8a constructs and 5 μl of Lipofectamine 2000
according to manufacturer’s instructions in full medium
overnight. The following day, cells were split at a 1:4 ra-
tio, plated onto coverslips, and processed 24 h later.
Primary human skin fibroblasts established from skin bi-
opsies taken from five age- and sex-matched healthy con-
trol and five PD patients with the G2019S mutation [8],
with informed consent and ethical approval, were grown in
IMDM and 10% fetal bovine serum, with media changed
every two days. Cells were subcultured at a ratio of
1:4, and seeded at equal densities on coverslips. All
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analyses were carried out on passages 3–8, and no
passage-dependent differences were observed.
For lymphoblast generation, three healthy control and
three PD patients due to the G2019S LRRK2 mutation
were recruited at the Movement Disorders Unit of Lille
University Medical Center (Lille, France, CPP Nord-Ouest
2008/09), with the two groups matched according to age
and gender. Blood samples were collected in BD Vacutai-
ner CPT Cell Preparation Tubes containing sodium hep-
arin (Le Pont-de-Claix, France). The peripheral blood
mononuclear cells (PBMCs) were collected and processed
according to supplier’s recommendations. Lymphocytes
were immortalized by infection with Epstein-Barr virus
(EBV) as described [30]. Briefly, cell lines were established
from freshly isolated lymphocytes or from cryopreserved
lymphocytes using standard EBV transformation protocols
that include cell separation by gradient centrifugation and
lymphocyte growth enhancement by the mitogen phyto-
hemagglutinin. Cell lines were maintained in RPMI 1640
medium supplemented with 20% fetal bovine serum,
L-glutamine, 20 units/ml penicillin and 20 μg/ml
streptomycin in T75 flasks in 5% CO2 at 37 °C. Cells were
maintained at a density of 106 cells/ml, with cell density
monitored every other day using trypan blue staining.
Where indicated, cells were treated with nocodazole
(200 nM, 2 h, SigmaAldrich), brefeldin A (5 μg/ml, 2 h,
SigmaAldrich), or the indicated concentrations of MLi2
(MRC PPU, Dundee, UK), LRRK2-IN1 (obtained through
the MJFF) or GSK2578215A (Tocris) before fixation.
DNA constructs and site-directed mutagenesis
GFP-tagged human LRRK2 constructs were obtained
from Addgene. Where required, mutations were intro-
duced by site-directed mutagenesis (QuikChange, Strata-
gene). The GFP-G2019S-K1906 M kinase-dead LRRK2
construct was generated by site-directed mutagenesis
introducing K1906 M on top of the G2019S construct,
and the identity of constructs verified by sequencing of the
entire coding region. DNA was prepared from bacterial
cultures grown at 28 °C using a midiprep kit (Promega) ac-
cording to manufacturer’s instructions. Human GFP-
tagged Rab8a, Rab8a-Q67L and Rab8a-T22 N, as well as
human GFP-tagged Rabin8 were obtained from Addgene.
mRFP-tagged or triple-flag (3xFlag)-tagged Rab8a con-
structs were generated using Gibson Assembly Master Mix
(New England Biolabs). Rab8a-T72A, Rab8a-T72D and
Rab8a-T72E mutant constructs were generated by site-
directed mutagenesis (QuikChange, Stratagene). The
siRNA-resistant forms of mRFP-Rab8a and mRFP-Rab8a-
T72A were generated by introducing 3 silent mutations
into the target sequence of the seed region of the Rab8a
siRNA (Silencer Select Rab8a (Ambion, ThermoFisher, ID
s8679, nr 4,390,824). Specifically, the original sequence of
the mRFP-Rab8a plasmids (5´-GCAAGAGAATTAAACT
GCA-3′) was mutated to 5´-GCAAGAGAATTAAGTT
ACA-3′). Identity of all constructs was verified by sequen-
cing of the entire coding region. HttQ74-GFP was a gener-
ous gift from D. Rubinsztein (Cambridge University, UK).
Immunofluorescence and laser confocal imaging
HEK293T cells were fixed using 2% paraformaldehyde
(PFA) in PBS for 10 min at room temperature, followed
by permeabilization in MeOH for 2 min at − 20 °C. Cells
were subsequently incubated in PBS containing 50 mM
NH4Cl for 10 min [31], and then permeabilized with
0.2% Triton-X100/PBS for 20 min. For determination of
the size of pericentrin-positive structures and for phospho-
Rab8a staining, the MeOH and NH4Cl steps were omitted.
HELA cells expressing GFP-tagged Rab8a constructs were
fixed using 4% PFA in PBS for 15 min at room temperature,
permeabilized with 0.5% Triton-X100/PBS for 5 min, rinsed
in PBS, and mounted with mounting medium containing
DAPI. SH-SY5Y cells were fixed using 2% paraformalde-
hyde (PFA) in PBS containing 4% sucrose for 20 min at
room temperature, followed by permeabilization with 0.2%
Triton-X100/PBS for 20 min. Primary fibroblasts were fixed
with 2% paraformaldehyde (PFA) in PBS for 10 min at
room temperature, followed by permeabilization with 0.2%
Triton-X100/PBS for 20 min.
For lymphoblast immunocytochemistry, 13 mm diameter
coverslips were placed into 24-well plates and coated with
Cell-Tak Cell and Tissue Adhesive solution (Corning) fol-
lowing manufacturer’s protocols. After 20 min at room
temperature, the solution was removed, coverslips were
rinsed twice with distilled water and air-dried. Lymphoblast
cells (200′000 per well) were added to dry coated cover-
slips, and cells attached by slight centrifugation at 690 g for
10 min at room temperature (without brake). Lymphoblast
cells were fixed using 2% PFA in PBS for 20 min at room
temperature, followed by permeabilization with 0.2%
Triton-X100/PBS for 20 min at room temperature.
After fixation and permeabilization, coverslips were
blocked for 1 h with 0.5% (w/v) BSA in 0.2% Triton-
X100/PBS (blocking solution), followed by incubation
with primary antibodies in blocking solution overnight
at 4°C. Primary antibodies included rabbit polyclonal
anti-pericentrin (Abcam, ab4448, 1:1000), mouse monoclo-
nal anti-pericentrin (Abcam, ab28144, 1:1000), mouse
monoclonal anti-γ-tubulin (Abcam, ab11316, 1:1000),
mouse monoclonal anti-c-Myc (Sigma, clone 9E10, M4439
1:500), mouse monoclonal anti-flag (Sigma, clone M2,
1:500), rabbit polyclonal anti-Rab8a (Millipore, ABC423,
1:1000), mouse anti-Golgin97 (Molecular Probes, A-21270,
1:100), rabbit polyclonal anti-β-COP (Invitrogen, PA1–061,
1:750), and mouse monoclonal p230/Golgin-245 (Becton
Dickinson, 611,280, 1:400). The sheep anti-Rab8a and anti-
T72-phospho-Rab8a antibodies have been previously de-
scribed (MRC PPU, S969D and S874D, respectively) [3].
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For the sheep anti-Rab8a antibody, the NH4Cl step was
omitted, and for the sheep anti-T72-phospho-Rab8a anti-
body, both the MeOH and NH4Cl steps were omitted.
Sheep antibodies were used at a 1:50 dilution, and
the anti-T72-phospho-Rab8a antibody was used in the
presence of a 10-fold molar excess of dephospho-
peptide, or of phospho-peptide where indicated. Im-
portantly, all double- and triple-immunocytochemistry
involving sheep antibodies were performed sequen-
tially, with the sheep antibodies employed first.
Secondary antibodies included Alexa 405-conjugated goat
anti-mouse or goat anti-rabbit, Alexa 488-conjugated goat
anti-mouse or goat anti-rabbit, Alexa 594-conjugated goat
anti-mouse or goat anti-rabbit, Alexa 633-conjugated goat
anti-mouse or goat anti-rabbit (Invitrogen, 1:1000), Alexa
488-conjugated donkey anti-sheep (Invitrogen, 1:1000) or
Alexa 594-conjugated donkey anti-sheep (Abcam, 1:1000).
As indicated, cells were either mounted using mounting
medium containing DAPI (Vector Laboratories), or incu-
bated with TO-PRO-3 Iodide (642/661) (Invitrogen,
1:1000) for 3 min, followed by washes in PBS before
mounting in ProLong Gold Antifade mounting medium
(Invitrogen).
Images were acquired on a Leica TCS-SP5 confocal
microscope using a 63X 1.4 NA oil UV objective (HCX
PLAPO CS). Images were collected using single excitation
for each wavelength separately and dependent on second-
ary antibodies (405 nm UV diode and a 415–455 nm
emission band pass; 488 nm Argon Laser line and a 510–
540 nm emission band pass; 543 HeNe Laser line and a
600–630 nm emission band pass; 633 HeNe Laser line
and a 640–670 nm emission band pass). GFP-tagged pro-
teins were excited with 488 nm Argon Laser line and a
500–530 nm emission band pass, and RFP-tagged proteins
with 543 nm HeNe Laser line and a 560–590 nm emission
band pass, respectively. DAPI was excited with the
405 nm UV diode and a 430–480 nm emission band pass,
and TO-PRO with 633 nm HeNe Laser line and a 650–
675 nm emission band pass, respectively.
10–15 image sections of selected areas were acquired
with a step size of 0.5 μm, and z-stack images analyzed
and processed using Leica Applied Systems (LAS
AF6000) image acquisition software. The same laser in-
tensity settings and exposure times were used for image
acquisition of individual experiments to be quantified.
For quantification of centrosome size, a circle was drawn
around individual centrosomes and area quantified using
image acquisition software as described above, where
mature centrosomes were around 1 μm2, and immature
centrosomes around 0.5 μm2. Centrosomes were scored
as being separated when the distance between their cen-
ters was > 1.5 μm (for HEK293T and SH-SY5Y cells) as
analyzed by ImageJ software. For fibroblasts, the mean
distance between separated centrosomes in control cells
was 2.25 ± 0.2 μm (mean ± s.e.m., n = 10 cells), and cen-
trosomes scored as being separated when the distance
was > 2.5 μm. Using equivalent criteria for lymphoblasts,
centrosomes were scored as being separated when the
distance was > 1.3 μm. In all cases, mitotic cells were ex-
cluded from this analysis.
Quantification of the phospho-Rab8a signal in SH-
SY5Y cells was done over non-processed and non-
saturated images acquired during the same day with the
same laser intensities. Quantification was performed
with Leica Applied Systems (LAS AF6000) image acqui-
sition software. Circular ROIs of 2.2 μm width and
2.2 μm height were set on top of the centrosomal signal,
and mean intensity from the phospho-Rab8a signal ob-
tained from at least 50 cells per condition and experi-
ment. Background signal was subtracted in all cases by
placing the ROI in a different aleatory place within the
same cell. Similarly, to quantify phospho-Rab8a signals
in lymphoblasts, a circle of 3 μm diameter was drawn
around individual centrosomes as assessed by pericen-
trin staining, and the phospho-Rab8a fluorescence inten-
sity from around 30–50 individual cells quantified from
maximal intensity projections using Leica Applied Sys-
tems (LAS AF6000) image acquisition software.
Most experiments were quantified by two independent
observers, and some experiments were quantified by a
third observer blind to condition, with similar results
obtained in all cases.
Knockdown of Rab8a by RNA interference
HEK293T cells were seeded in 6-well plates at 30–40%
confluence one day prior to transfection such that they
were at a confluence of 70–80% the following day. They
were transfected with 2 μg of GFP-LRRK2 DNA and
25 nM siRNA using 4 μl of jetPRIME Transfection Re-
agent (Polyplus-Transfection SA, no 114–15) in 200 μl
jetPRIME buffer. The mix was incubated for 15 min at
room temperature and added to 2 ml of full medium per
well of a 6-well plate overnight. For knockdown experi-
ments in the presence of both GFP-LRRK2 and mRFP-
Rab8a or mRFP-Rab8a-T72A (sensitive or resistant to
siRNA, respectively), cells were transfected with 50 nM
of the indicated siRNA using 4 μl of jetPRIME Transfec-
tion Reagent as described above. Four hours later, media
was replaced and cells transfected with 2 μg of the indi-
cated LRRK2 constructs and 200 ng of the indicated
Rab8a constructs and 6 μl of LipoD293 (SignaGen Labora-
tories) per well of a 6-well plate overnight in full medium.
In all cases, cells were passaged 24 h later and processed
for Western blot analyis or immunocytochemistry 48 h
after transfection. RNAi reagents included Silencer Select
Negative Control no. 1 siRNA (Ambion, ThermoFisher,
cat. nr 4,390,843) and Silencer Select Rab8a (Ambion,
ThermoFisher, ID s8679, cat. nr 4,390,824).
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For determination of Rab8a levels, cells were washed
in PBS and resuspended in cell lysis buffer (1% SDS in
PBS containing 1 mM PMSF, 1 mM Na3VO4, 5 mM
NaF). Extracts were sonicated, boiled and centrifuged at
13,500 rpm for 10 min at 4 °C. Protein concentration of
supernatants was estimated using the BCA assay
(Pierce), and 30 μg of extracts resolved by SDS-PAGE
and analyzed by Western blotting.
Wound healing and cell migration assays
For wound-healing assays, 40,000 SH-SY5Y cells were
seeded on each side of 35 mm insert-containing dishes
(IBIDI) and grown to confluence in full medium. The
wound (500 μm diameter) was generated by removing
the insert, cells were gently washed three times in full
medium, and phase contrast images acquired every
10 min for 15 h on a Leica TCS-SP5 confocal micro-
scope using a 10X objective (C-PLAN 10.0 × 0.22 POL)
and 1.3X zoom. Overall wound healing migration speed
was calculated as average speed of the cell front using
ImageJ software analysis. For single cell tracking, indi-
vidual cells in the first row facing the wound were
tracked (ImageJ manual tracking plugin) until reaching
the middle of the wound [32], and individual cell migra-
tion speed, directionality (D) and forward migration
index in Y (FMI Y) calculated from at least 30 cells per
condition and experiment using the Chemotaxis and
Migration Tool (IBIDI).
For determination of cell polarity, cells were processed
for immunocytochemistry 4 h after generating the wound
using anti-pericentrin and anti-golgin97 antibodies as de-
scribed above. The first row of cells facing the wound
was analyzed, and cells were scored as polarized when
located in a 90° sector emerging from the center of
the nucleus and facing the wound edge [33]. Basal
levels of expected random orientation of 25% were
confirmed by analyzing centrosome orientation imme-
diately after generating the wound.
Cell extracts and western blotting
HEK293T cells were collected 48 h after transfection,
washed in PBS and resuspended in cell lysis buffer (1%
SDS in PBS containing 1 mM PMSF, 1 mM Na3VO4,
5 mM NaF). Extracts were sonicated, boiled and centri-
fuged at 13,500 rpm for 10 min at 4 °C. Protein concen-
tration of supernatants was estimated using the BCA
assay (Pierce), and 40 μg of extracts resolved by SDS-
PAGE and analyzed by Western blot, using a rabbit
polyclonal anti-GFP antibody (ab6556, 1:3000, Abcam),
phospho-S935-LRRK2 antibody (ab133450, Abcam,
1:500), a mouse monoclonal anti-myc antibody (clone
9E10, 1:1000, Sigma), a sheep polyclonal anti-Rab8a (MRC
PPU, S969D, 1:200), a sheep polyclonal anti-phospho-
Rab8a (MRC PPU, S874D, 1:200), a mouse monoclonal
anti-flag antibody (clone M2, 1:2000, Sigma) and a mouse
monoclonal anti-tubulin antibody (clone DM1A, 1:10,000,
Sigma) as loading control.
For lymphoblast cell extracts, 106 cells were centri-
fuged at 1030 g for 10 min at 4 °C. The pellet was resus-
pended in 100 μl of lysis buffer (20 mM Tris-HCl
pH 7.4, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1%
Triton-X100) containing protease and phosphatase in-
hibitor cocktails (SigmaAldrich), and incubated for
30 min on a rotary wheel at 4 °C. Cell extracts were cen-
trifuged at 13,500 rpm for 5 min at 4 °C, and superna-
tants quick-frozen in liquid N2 and stored at − 80 °C.
Protein concentration of supernatants was estimated
using the BCA assay (Pierce), and 20 μg of extracts re-
solved by SDS-PAGE and analyzed by Western blot,
using a rabbit polyclonal phospho-S935-LRRK2 antibody
(ab133450, Abcam, 1:500), a mouse monoclonal anti-
LRRK2 antibody (UC Davies/NIH NeuroMab clone 75–
253, 1:1000), a sheep polyclonal anti-Rab8a (MRC PPU,
S969D, 1:200) and a mouse monoclonal anti-tubulin
antibody (clone DM1A, 1:10,000, Sigma) as loading con-
trol. Some Westerns were developed with ECL reagents
(Roche), and a series of timed exposures to ensure that
densitometric analyses were performed at exposures
within the linear range. Quantification was performed
using QuantityOne software (BioRad). Western blotting
of phospho-S935 and total LRRK2 in extracts from lym-
phoblasts was performed with ECL Prime Western
Blotting Detection Reagent (GEHealthcare), and analysis
in Amersham Imager 600 (GEHealthcare). The majority
of Western blotting was performed according to the
protocol described by LI-COR for Near-Infrared West-
ern Blot Detection. In all cases, incubation with primary
antibodies was performed overnight at 4 °C, and second-
ary antibodies were incubated for 1 h at RT. For analysis
of Rab8a or phospho-Rab8a levels using this technology, a
rabbit monoclonal anti-Rab8a antibody (ab188574, Abcam,
1:1000), and a rabbit polyclonal phospho-Rab8a antibody
were employed. Blots were imaged using an Odyssey CLx
system, and quantification was done using the instrument’s
Image Studio software.
Immunoprecipitation of GFP-Rabin8
HEK293T cells were cultured as described and co-
transfected at 80% confluence with 600 ng of GFP-
Rabin8 and 200 ng of flag-tagged Rab8a constructs using
6 μl of LipoD293 (SignaGen Laboratories) per well of a
6 well plate overnight in full medium. The following day,
cells were split into 100 mm tissue culture plates, and
were collected 48 h after transfection. Cells were washed
in PBS, followed by resuspension in 1 ml of lysis buffer
(50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 2 mM MgCl2,
1% Triton-X100, 1 mM DTT, protease inhibitor cocktail
(Roche) and phosphatase inhibitor cocktail 3 (Sigma)),
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and incubated on a rotary wheel for 1 h at 4 °C. Lysates
were subsequently spun at 13′000 rpm for 10 min at 4 °C,
and protein concentration of supernatants estimated by
BCA assay (Sigma), with 1 mg of total protein subjected
to immunoprecipitation with a rabbit polyclonal anti-GFP
antibody (Abcam, Ab 6556, 1 μg per sample). Lysates were
incubated with antibody for 2 h at 4 °C, followed by
addition of protein G Sepharose Fast Flow (Amersham)
and incubation overnight at 4 °C. The next day, beads
were washed three times with lysis buffer, and bound pro-
teins eluted with Laemmli sample buffer and heating at
95 °C for 4 min prior to separation by SDS-PAGE and
Western blotting as indicated above, using a mouse
monoclonal anti-GFP antibody (Roche, 1:1000) or a
mouse monoclonal anti-flag antibody (clone M2, 1:1000,
Sigma), respectively.
Cell transfection, protein purification and in vitro kinase
assays
HEK293T cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (v/v)
fetal bovine serum, penicillin (100 units/ml) and strepto-
mycin (100 μg/ml) (Life Technologies) at 37 °C and 5%
CO2. 3xFlag-LRRK2 (wildtype and G2019S mutant) and
3xFlag-Rab8a (wildtype and T72A mutant) were transi-
ently transfected using linear polyethylenimine (PEI,
Polyscience) with a 1:2 DNA:PEI ratio. The transfection
mixes were prepared by dissolving 40 μg of DNA in
1 ml of OPTI-MEM with 80 μl of PEI (40 μM final).
Mixes were incubated at room temperature for 20 min
and subsequently added to HEK293T cells previously
plated on a 15 cm2 Petri dish.
Seventy-two hours after transfection, cells were resus-
pended in 1 ml of lysis buffer (10 mM Tris-HCl pH 7.5,
150 mM NaCl, 5 mM EDTA, 2.5 mM Na4P2O7, 1 mM
beta-glycerophosphate, 1 mM Na3VO4, supplemented
with protease inhibitor mixture (Sigma-Aldrich) and 1%
(v/v) Tween-20). Samples were left on ice for 30 min,
and cell lysates collected after centrifugation at 18000×g
for 35 min at 4 °C. Supernatants were collected and in-
cubated overnight with 40 μl of Anti-Flag M2 Affinity
Gel beads (Sigma-Aldrich) at 4 °C with mild agitation.
Beads were pelleted and washed with 1 ml of five differ-
ent wash buffers (WB): WB1 (20 mM Tris-HCl pH 7.5,
500 mM NaCl, 1% (v/v) Tween-20) twice, WB2 (20 mM
Tris-HCl pH 7.5, 350 mM NaCl, 1% (v/v) Tween-20)
twice, WB3 (20 mM Tris-HCl pH 7.5, 150 mM NaCl,
1% (v/v) Tween-20) twice, WB4 (20 mM Tris-HCl
pH 7.5, 150 mM NaCl, 0.1% (v/v) Tween-20) twice and
WB5 (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.02%
(v/v) Tween-20) once. All 3xFlag-tagged proteins were
eluted in elution buffer (25 mM Tris-HCl pH 7.5, 5 mM
beta-glycerophosphate, 2 mM DTT, 0.1 mM Na3VO4,
10 mM MgCl2 supplemented with 0.007% Tween-20,
150 ng/μl 3xFlag peptide (Sigma-Aldrich) for subsequent
in vitro kinase assays.
For experiments in which Rab8a was loaded with spe-
cific guanine nucleotides, affinity resin bound-protein
was washed as above, rinsed in loading buffer (20 mM
Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.02% (v/v)
Tween-20) and incubated with an excess (200 μM) GDP or
GTPγS for 30 min at 30 °C with slight agitation. Nucleotide
exchange was stopped and excess nucleotides removed by
rinsing beads three times in kinase buffer (25 mM Tris-HCl
pH 7.5, 10 mM MgCl2, 2 mM dithiothreitol (DTT), 0.02%
(v/v) Tween-20, 5 mM beta-glycerophosphate, 0.1 mM
Na3VO4) [34] followed by elution with kinase buffer sup-
plemented with 150 ng/μl 3xFlag peptide.
For in vitro kinase assays, purified wildtype or T72A-
mutant 3xFlag-Rab8a proteins eluted in kinase buffer,
with and without nucleotide loading, were incubated
with wildtype or G2019S mutant 3xFlag-LRRK2 at a ra-
tio of 50:1 (Rab8a:LRRK2). Reactions were kept at 30 °C
for 1 h in the presence of ATP-γ33P (1 μCi/reaction) and
2.5 μM cold ATP and then stopped by adding Laemmli
buffer (100 mM Tris-HCl pH 6.8, 4% (w/v) SDS,
200 mM DTT, 20% (v/v) glycerol and Bromophenol Blue).
Incorporated 33P was detected by autoradiography with
a Phospho-Imager system (Cyclone, Perkin-Elmer). The
same membranes were stained with Coomassie Blue or
probed with an anti-Flag antibody for total protein load-
ing, and quantification performed using ImageJ software.
Rab8a GTP binding and GTP retention assays
HEK293T cells were transfected with 3xFlag-Rab8a wild-
type or mutant plasmids as indicated and 24 h later cells
were lysed in buffer containing 20 mM Tris-HCl pH 7.5,
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10%
glycerol and protease inhibitor cocktail (Roche) for 30 min
on ice. Lysates were centrifuged (10 min, 20,000×g), super-
natants were precleared with Easy view Protein G agarose
(Sigma-Aldrich) for 30 min at 4 °C, followed by incubation
with anti-Flag M2 agarose beads (Sigma-Aldrich) for 1 h at
4 °C with mild agitation. Proteins bound to beads were
washed 4 times with 25 mM Tris-HCl pH 7.5, 400 mM
NaCl, and 1% Triton X-100.
For GTP or GDP binding assays, equal amounts of
wildtype or mutant 3xFlag-Rab8a fusion proteins bound to
anti-Flag M2 agarose beads (Sigma-Aldrich) were washed
twice with Buffer A (20 mM Tris–HCl pH 7.5, 100 mM
NaCl, 5 mMMgCl2, 1 mM NaH2PO4, 2 mM DTT) and in-
cubated overnight on ice in Buffer A containing 0.1 μM
3H–GTP or 3H–GDP. Beads were then washed twice in
Buffer A to remove unbound nucleotides, added to Bio-
safe II (RPI) scintillation cocktail, and binding quantified
using scintillation counting for H3 (Tri-Carb 2810TR scin-
tillation counter, Perkin Elmer).
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To assay GTP or GDP retention, agarose-bound Rab8a
proteins were incubated in Buffer A containing 0.1 μM
3H–GTP or 3H–GDP overnight on ice and washed twice
with Buffer A to remove unbound nucleotide. Subse-
quently, proteins were incubated in Buffer A containing a
100-fold excess of unlabeled GTP or GDP for 0, 15, 30 or
60 min, and shaking at 37 °C. After each time point, Rab8a
proteins were washed twice with Buffer A, and retained
3H–GTP or 3H–GDP bound to proteins was quantified
using scintillation counting. The amount of 3H–GTP or
3H–GDP bound at 15, 30 and 60 min for each sample was
calculated as a fraction of initial binding.
Co-immunoprecipitation
HEK293FT cells transfected with 3xflag-Rab8a plasmids
were lysed in IP buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 1 mM EDTA, 0.3% Triton X-100, 10% Gly-
cerol, and protease inhibitor cocktail (Roche)) for 30 min
on ice. Lysates were centrifuged at 4 °C for 10 min at
20,000 g and supernatants were further cleared by incuba-
tion with Easy view Protein G agarose beads (Sigma) for
30 min at 4 °C. After agarose bead removal by centrifuga-
tion, lysates were incubated with anti-flag M2 agarose
beads (Sigma) for 1 h at 4 °C with mild agitation. Beads
were washed three times with IP wash buffer (20 mM Tris-
HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% Triton X-
100, 10% Glycerol) and eluted in buffer containing 20 mM
Tris-HCl, 100 mM NaCl, 5 mM MgCl2 and 150 ng/μl of
3xflag peptide by shaking for 15 min at 4 °C. Each co-
immunoprecipitation was repeated in 3 independent exper-
iments, and samples analyzed by Western blotting using an
anti-GDI1/2 antibody (1:2000, Life Technologies, 710,300)
or an anti-flag antibody (1:500, Sigma, F3165).
Mass spectrometry
Purified wildtype and mutant Rab8a proteins were sepa-
rated on 4–20% SDS-PAGE, stained with Coomassie
brilliant blue staining (Thermo Scientific) and a band
corresponding to a ~ 50 kDa protein was excised. Pro-
tein identification was performed using MASCOT.
Statistical analysis
All data are expressed as means ± s.e.m. Unless otherwise
noted, data were analyzed by one-way ANOVA with
Tukey’s post-hoc test, and p < 0.05 was considered signifi-
cant. Statistical details to all experiments can be found in
the figure legends. ***p < 0.005; **p < 0.01; *p < 0.05.
Results
Pathogenic LRRK2 causes deficits in centrosomal
positioning critical for cell polarization and directed
migration
To evaluate effects of pathogenic LRRK2 on cell polarity,
we employed human neuroblastoma SH-SY5Y cells stably
expressing flag-tagged wildtype or G2019S mutant LRRK2
[28, 29]. Cells were differentiated with retinoic acid, and
average neurite length quantified. Pathogenic G2019S
LRRK2-expressing cells showed a significant decrease in
the percentage of differentiated cells as compared to con-
trol or wildtype LRRK2-expressing cells (Fig. 1a-c). Since
proper positioning of the centrosome is important for cell
polarization and directed migration [24, 25], we analyzed
centrosome positioning from non-contiguous differenti-
ated cells by staining for pericentrin, a component of the
pericentriolar matrix [35]. The centrosome was facing the
longest neurite in the majority of control and wildtype
LRRK2-expressing cells, whilst a significant amount of
G2019S-expressing cells had their centrosome positioned
on the side, or opposite the longest neurite (Fig. 1d and e).
As cell polarization is a prerequisite for cell migration
[25], we wondered whether pathogenic LRRK2-expressing
cells display deficits in cell migration associated with al-
tered centrosome positioning. Scratch wounding was
performed on control GFP, wildtype or G2019S mutant
LRRK2-expressing SH-SY5Y cells, and cells counted as ori-
ented when the centrosome was located within a 90° angle
facing the wound [32, 33, 36] (Fig. 2a). After 4 h of wound-
ing, around 40% of control GFP and wildtype LRRK2-
expressing cells had already reoriented the centrosome,
whilst the percentage of reoriented centrosomes was sig-
nificantly less in G2019S LRRK2-expressing cells (Fig. 2b).
To test for potential migration defects, cells were recorded
by live cell microscopy after performing a scratch wound
(Fig. 2c and d). G2019S-LRRK2-expressing cells displayed
a decrease in cell migration in the wound healing assay as
compared to wildtype LRRK2-expressing cells. Whereas
wildtype LRRK2-expressing cells exhibited persistent
directional migration until the closure of the gap,
G2019S-LRRK2-expressing cells displayed less direc-
tional migration, without a reduction in cell motility
(Fig. 2e and f). Together, these data indicate that mutant
LRRK2 causes deficits in proper centrosome positioning
with effects on polarity required for cells to properly re-
spond to directional migration signals.
Distinct pathogenic LRRK2 mutants cause centrosomal
cohesion deficits in a kinase activity-dependent manner
In dividing cells, centrosomes duplicate in S phase, but are
held together by a flexible linker which gradually elongates
during S and G2, allowing the duplicated centrosomes to
mature by accumulating pericentriolar material. At the
G2/M transition, the flexible linker holding the centro-
somes together is lost, and mature centrosomes can subse-
quently constitute the poles of the mitotic spindle [26]. To
determine for possible centrosomal alterations in dividing
cells, we examined cells with duplicated centrosomes from
non-differentiated SH-SY5Y cells. When quantifying cells
where duplicated centrosomes could be clearly visualized
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as separate from each other, the mean distance between
duplicated split centrosomes in GFP expressing cells was
1.49 ± 0.07 μm (mean ± s.e.m., n = 13 cells), and centro-
somes were therefore scored as split when > 1.5 μm apart.
As compared to GFP or wildtype LRRK2, pathogenic
G2019S LRRK2 was found to significantly increase the per-
centage of cells with split centrosomes, indicative of a cen-
trosomal cohesion deficit (Fig. 3a and b). To assess whether
such centrosomal alterations induced by mutant LRRK2
were dependent on LRRK2 kinase activity, we evaluated the
effects of two structurally distinct and specific LRRK2
kinase inhibitors, and quantified dephosphorylation of S935
on LRRK2 as an established readout for kinase inhibition
[37, 38]. Short-term addition of these inhibitors significantly
reverted the observed cohesion deficits in G2019S-LRRK2
expressing cells (Fig. 3c) and inhibited kinase activity as
assessed by S935 dephosphorylation (Fig. 3d, e), suggesting
that these cohesion deficits are kinase activity-mediated.
We next wondered whether the centrosomal cohesion
deficits comprised a phenotype shared amongst distinct
pathogenic LRRK2 mutants. For this purpose, HEK293T
cells were transiently transfected with various mutant
LRRK2 constructs. Similar to SH-SY5Y cells, the mean
distance between duplicated split centrosomes in non-
Fig. 1 Pathogenic LRRK2 causes deficits in differentiation and altered centrosome positioning in differentiated SH-SY5Y cells. a Quantification of
neurite length in SH-SY5Y cells differentiated with retinoic acid for 5 days. Around 150 cells were analyzed per condition and experiment. Bars
represent mean ± s.e.m., (n = 3 independent experiments); *, p < 0.05. b Quantification of neurite length only including differentiated cells. Around
150 differentiated cells were analyzed per condition and experiment. Bars represent mean ± s.e.m., (n = 3 independent experiments). c Quantification of
percentage of differentiated cells. Bars represent mean ± s.e.m., (n = 3 independent experiments); *, p < 0.05. d Quantification of differentiated cells where
centrosome is positioned on the side or opposite the longest neurite in the distinct cells as indicated. Around 30 non-contiguous differentiated cells were
analyzed per condition and experiment. Bars represent mean ± s.e.m., (n = 3 independent experiments); *, p < 0.05. e Example of non-contiguous SH-SY5Y
cells stably expressing GFP, or flag-tagged wildtype or G2019S-mutant LRRK2 as indicated, and stained for pericentrin and DAPI. Scale bar, 10 μm
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transfected HEK293T cells was 1.38 ± 0.05 μm (mean ±
s.e.m., n = 12 cells), and centrosomes were scored as split
when > 1.5 μm apart. As compared to non-transfected cells
or to cells expressing wildtype LRRK2, a larger percentage
of duplicated centrosomes displayed a split phenotype in
cells expressing either G2019S-, R1441C- or Y1699C-
mutant LRRK2, respectively, which was not observed with
a kinase-dead G2019S-K1906 M mutant (Additional file 1:
Figure S1a and b), even though all LRRK2 variants were
expressed to similar degrees (Additional file 1: Figure S1c).
As previously described [19], under the overexpression
conditions in HEK293T cells employed here, pathogenic
mutant LRRK2 also displayed more visible accumulation at
and/or around centrosomes as compared to wildtype or
kinase-inactive G2019S-K1906 M mutant LRRK2, which
were cytosolic in the majority of cells (Additional file 1:
Fig. 2 Pathogenic LRRK2 causes deficits in centrosomal positioning critical for cell polarization and directed migration. a Example of reorientation
of the centrosome 4 h after wounding in SH-SY5Y cells stably expressing flag-tagged wildtype or G2019S mutant LRRK2. The white lines indicate
scratch orientation, and cells were stained with anti-pericentrin, anti-Golgin97, and DAPI. Angles are labeled as having oriented (+) or not oriented
(−) centrosomes for the first row of cells facing the scratch wound. Scale bar, 10 μm. b Quantification of centrosome reorientation in cells stably
expressing GFP, flag-tagged wildtype or G2019S-mutant LRRK2 immediately after (t = 0 h), or 4 h after generating the wound (t = 4 h). Random
orientation is expected to be 25%. N > 100 cells were quantified for each condition in each experiment. Bars represent mean ± s.e.m. (n = 3 independent
experiments); **, p < 0.01. c Wound-healing assays in either flag-tagged wildtype or G2019S-mutant LRRK2-expressing SH-SY5Y cells. Phase-contrast
images at the indicated times are shown. Scale bar, 150 μm. d Quantitative analysis of wound-healing assays as described in Methods. Bars represent
mean ± s.e.m. (n = 6 independent experiments); ****, p < 0.001. e Example of tracking of individual cells expressing flag-tagged wildtype or G2019S
mutant LRRK2. Individual cells in the first row facing the wound were tracked until reaching the middle of the wound. Directionality index (D) and
forward migration index in Y axis (FMI Y) were calculated for at least 30 cells per condition in three independent experiments, and are expressed as
mean ± s.e.m. on top of each graph. *, p < 0.05. f Single cell wound healing migration speed was calculated for at least 30 cells per condition in 3
independent experiments
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Figure S1a and d), and additional localization of R1441C
and Y1699C mutant LRRK2 to filamentous structures
could be observed in some cells as well (Additional file 1:
Figure S1e) [39]. Alterations in centrosomal cohesion
were not due to aggregation-related events of LRRK2
protein overexpression, as triggering the formation of
pericentrosomal protein aggregates (aggresomes) either by
proteasomal inhibition in LRRK2-expressing cells, or by
overexpression of a mutant version of huntingtin protein,
did not cause centrosome splitting (Additional file 1:
Figure S1f). Consistent with premature centrosome split-
ting in pathogenic LRRK2-expressing cells, the duplicated
Fig. 3 Pathogenic LRRK2 causes deficits in centrosome cohesion in SH-SY5Y cells. a Example of non-differentiated SH-SY5Y cells stably expressing
GFP, or flag-tagged wildtype or G2019S-mutant LRRK2 as indicated, and stained for pericentrin and DAPI. Scale bar, 10 μm. b Quantification of
the split centrosome phenotype in cells expressing GFP, or flag-tagged wildtype or G2019S-mutant LRRK2 as indicated. Around 20 cells with
duplicated centrosomes were analyzed per condition. Bars represent mean ± s.e.m. (n = 4 independent experiments); *, p < 0.05. c Quantification
of the split centrosome phenotype in cells expressing flag-tagged wildtype or G2019S-mutant LRRK2 as indicated, in either the absence or presence of
kinase inhibitors (500 nM LRRK2-IN-1 or GSK2578215A for 1 h) as indicated. Around 20 cells with duplicated centrosomes were analyzed per condition.
Bars represent mean ± s.e.m. (n = 3 independent experiments); **, p < 0.01; *, p < 0.05. d Cells were either left untreated or incubated with 500 nM
GSK2578215A for 1 h, and extracts analyzed for phosphorylated (p-S935) or total (flag) LRRK2. e Quantification of S935 dephosphorylation in cells
expressing flag-tagged wildtype or G2019S-mutant LRRK2 as indicated, in either the absence or presence of 500 nM GSK2578215A for 1 h. Bars
represent mean ± s.e.m. (n = 3); *, p < 0.05
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centrosomes were smaller than normal, mature centro-
somes as determined in control or wildtype LRRK2-
transfected cells (Additional file 1: Figure S1g and h).
Thus, the observed centrosomal cohesion deficits seem to
be a cellular feature shared amongst all three pathogenic
LRRK2 mutants.
To assess whether premature centrosome splitting in-
duced by mutant LRRK2 was dependent on LRRK2 kinase
activity, we evaluated the effects of two distinct and select-
ive LRRK2 kinase inhibitors [37, 38]. Addition of either in-
hibitor to wildtype LRRK2-expressing cells caused rapid
recruitment of LRRK2 to the centrosome, but such centro-
somal localization of kinase-inhibited LRRK2 did not cause
centrosome splitting (Additional file 2: Figure S2a-c). How-
ever, whilst not causing a change in the centrosomal
localization of pathogenic LRRK2 (Additional file 2: Figure
S2d), treatment with either inhibitor reversed centrosome
splitting in mutant LRRK2-expressing cells (Additional file
2: Figure S2e). Inhibitor-mediated reversal of centrosomal
cohesion deficits were observed with all three pathogenic
LRRK2 mutants (Additional file 2: Figure S2e,f), indicating
that premature centrosome splitting is a shared feature of
distinct pathogenic LRRK2 mutants and mediated by the
kinase activity in both HEK293T and SH-SY5Y cells.
Centrosomal cohesion deficits are detectable in two distinct
peripheral cell types from LRRK2 PD patients as compared
to healthy controls
LRRK2 is known to be expressed in non-neuronal cells
such as fibroblasts or lymphoblasts [40], and these
patient-derived cells may comprise promising cellular
models for future pharmacodynamic assays in clinical
studies employing LRRK2 kinase inhibitors. Therefore, we
next used either skin fibroblasts or lymphoblasts from
age- and sex-matched G2019S mutant LRRK2 PD patients
and healthy controls, respectively. Primary fibroblasts
from five G2019S mutant LRRK2 PD patients displayed
increased centrosome splitting as compared to five control
patients, which was reverted by application of either
GSK2578215A or LRRK2-IN-1 kinase inhibitors, respect-
ively (Fig. 4a and b). Similarly, lymphoblasts from three
G2019S mutant LRRK2 PD patients displayed deficits in
centrosomal cohesion as compared to three healthy con-
trol cells. Such deficits were reverted by application of
500 nM GSK2578215A kinase inhibitor (Fig. 4c and d). In
addition, application of either 10 nM or 100 nM of MLi2,
a recently developed novel and highly selective LRRK2
kinase inhibitor [41] also reverted the centrosomal
cohesion deficits (Fig. 4c and d), and inhibited LRRK2
kinase activity as assessed by S935 dephosphorylation
(Fig. 4e and f). Together, these data indicate that endogen-
ous mutant LRRK2 protein causes centrosomal alterations
in a kinase activity-dependent manner also in two distinct
patient-derived cell types.
Pathogenic LRRK2-induced centrosomal cohesion deficits
correlate with aberrant centrosomal accumulation of
phosphorylated Rab8a
We next aimed to determine the mechanism(s) by which
pathogenic LRRK2 may cause the observed centrosomal
alterations. Recent studies have identified a subset of Rab
GTPases as LRRK2 kinase substrates, with Rab8a being
one of the most prominent substrates [3], and known to
be involved in centrosome-related events. Indeed, we con-
firmed that Rab8a was subject to phosphorylation by
LRRK2 in vitro, that phosphorylation was increased with
pathogenic as compared to wildtype LRRK2, and that
phosphorylation was largely abolished when mutating the
previously identified phosphorylation site (T72) in the
switch II domain (Additional file 3: Figure S3a and b).
Moreover, we found that phosphorylation was not altered
by either GDP or GTP binding to Rab8a (Additional file 3:
Figure S3a-d), indicating that it was not dependent on the
nucleotide-bound status of Rab8a.
Rab proteins interact with a variety of regulatory proteins.
For example, the localization of Rab proteins is regulated
by binding to GDP dissociation inhibitor (GDI1/2), which
is able to deliver as well as extract Rab proteins from
membranes [42], and their activity is modulated by
binding to GDP/GTP exchange factors (GEFs) [43].
To test for differential interactions with regulatory pro-
teins, we next generated phospho-deficient (Rab8a-T72A)
and phospho-mimetic (Rab8a-T72D/Rab8a-T72E), as
well as GTP-preferring (Rab8a-Q67L) and GDP-preferring
(Rab8a-T22 N) Rab8a variants, which were all expressed to
similar degrees (Additional file 3: Figure S3e). All mutants
with the exception of Rab8a-T22 N were competent to bind
GTP and GDP, and the rates of GTP/GDP dissociation
were not affected by the mutations, indicating that mimick-
ing phosphorylation does not change the nucleotide state
of Rab8a (Additional file 3: Figure S3f-i). As previously de-
scribed [3], whilst GDI1/2 coimmunoprecipitated with
wildtype Rab8a as determined by mass spectroscopy, this
interaction was lost with the phospho-mimetic Rab8a mu-
tants (Additional file 4: Figure S4a-c), which also displayed
a decreased interaction with the GEF Rabin8 (Rab3IP)
(Additional file 4: Figure S4d and e), suggesting that mim-
icking Rab8a phosphorylation interferes with its interaction
with multiple regulatory proteins. When expressed on their
own, phospho-mimetic Rab8a mutants did not cause cen-
trosomal cohesion deficits and were found to be largely
cytosolic (Additional file 4: Figure S4f,g). Thus, these mu-
tants cannot properly mimick a phosphorylated version of
Rab8a in a cellular context.
Rab8a has been shown to be localized to a pericentro-
somal recycling compartment which is in direct contact
with the centrosome to regulate a variety of centrosome-
related events [20–22]. We thus wondered whether
pathogenic LRRK2 may alter the subcellular localization
Madero-Pérez et al. Molecular Neurodegeneration  (2018) 13:3 Page 11 of 22
Fig. 4 (See legend on next page.)
Madero-Pérez et al. Molecular Neurodegeneration  (2018) 13:3 Page 12 of 22
of endogenous Rab8a. Whilst endogenous Rab8a was
rarely localized to a pericentrosomal/centrosomal com-
partment in control cells, all pathogenic LRRK2 mutants
caused a prominent increase in the amount of cells dis-
playing pericentrosomal/centrosomal Rab8a accumula-
tion (Fig. 5a and b) without changes in the total levels of
endogenous Rab8a protein (Fig. 5c).
Rab8a can also localize to the Golgi complex which is
in tight contact with the centrosome [24, 44], and such
centrosome-Golgi nexus is known to be important for cell
polarity [45]. To determine whether the pericentrosomal/
centrosomal accumulation of Rab8a is reflective of en-
hanced Golgi association, non-transfected or LRRK2-
transfected cells were either treated with nocodazole,
which causes Golgi fragmentation and dispersal, or with
brefeldin A, which causes redistribution of the Golgi com-
plex into the ER [46]. Golgi dispersal or complete Golgi
redistribution did not alter the accumulation of Rab8a in
pathogenic LRRK2-expressing cells (Additional file 5:
Figure S5), indicating that Rab8a genuinely associates with
a centrosomal/pericentrosomal compartment.
The centrosomal/pericentrosomal Rab8a accumulation
was reverted upon application of the LRRK2 kinase in-
hibitor GSK2578215A (Fig. 5a and b). Whilst S935 phos-
phorylation is a reliable readout to determine whether
pharmacological kinase inhibitors block the LRRK2 kinase
activity, it is not predictive of kinase activity of pathogenic
mutants per se [47–53]. Indeed, whilst varying S935 phos-
phorylation levels were detected in wildtype and mutant
LRRK2, application of GSK2578215A effectively inhibited
the activity of both wildtype and mutant LRRK2 variants
as measured by S935 dephosphorylation (Fig. 5d, e). Fur-
thermore, Rab8a accumulation was not observed when
expressing the kinase-dead pathogenic LRRK2 mutant
G2019S-K1906 M (Fig. 5b). We thus wondered whether
the accumulating Rab8a species may be a phosphorylated
version of the protein. For this purpose, non-transfected
or pathogenic LRRK2-transfected cells were stained
with an antibody raised for the specific detection of
phospho-T72-Rab8a [3]. Mutant LRRK2 expression caused
a centrosomal/pericentrosomal accumulation of phosphor-
ylated Rab8a, which was not observed when preincubating
the phospho-antibody with phospho-peptide, and was re-
versed upon pretreatment of cells expressing either patho-
genic G2019S, R1441C or Y1699C LRRK2 with MLi2
(Fig. 6a-c). Therefore, the accumulating Rab8a species in
LRRK2-expressing HEK293T cells seems to represent a
phosphorylated version of the protein.
Amongst all cell types analyzed here, lymphoblasts
seem to contain the highest levels of endogenous Rab8a
(Additional file 6: Figure S6a). We therefore attempted to
determine whether alterations in endogenous phospho-
Rab8a accumulation could be detected in lymphoblasts de-
rived from G2019S LRRK2-PD patients as compared to
healthy controls. No significant differences in the total
levels of Rab8a were detected between lymphoblasts from
control versus G2019S LRRK2-PD patients (Additional file
6: Figure S6b and c). Staining with the phospho-Rab8a anti-
body revealed a pericentrosomal/centrosomal accumula-
tion of phospho-Rab8a in control and G2019S LRRK2-PD
samples, which was absent when preincubating the anti-
body with phosphopeptide (Additional file 6: Figure S6d).
Quantification of the intensity of the fluorescence signal re-
vealed a slight, but not significant increase in phospho-
Rab8a staining in G2019S LRRK2-PD samples as compared
to controls (Additional file 6: Figure S6e), suggesting that
higher affinity phospho-antibodies will be required to de-
tect possible changes in the localization of endogenous
phosphorylated Rab8a.
The phospho-Rab8a antibody was also not able to detect
differences in the centrosomal accumulation of endogenous
phospho-Rab8a in wildtype versus G2019S LRRK2-mutant
SH-SY5Y cells (Fig. 7a and b). Therefore, as a means to
increase phosphorylated Rab8a species, we expressed
wildtype Rab8a in either wildtype or G2019S LRRK2-
mutant SH-SY5Y cells. Under these conditions, a drastic
increase in Rab8a phospho-signal was observed (Fig. 7c
and d), which was abolished when pretreating cells with a
LRRK2 kinase inhibitor, and which was not observed
when expressing the non-phosphorylatable Rab8a-T72A
mutant (Fig. 7b-d), indicating that it was specifically de-
tecting a LRRK2-phosphorylated version of Rab8a. Even
though the expressed RFP-tagged Rab8a protein was
widely distributed, the phospho-Rab8a signal was confined
(See figure on previous page.)
Fig. 4 Centrosome splitting in human dermal fibroblasts and lymphoblasts from G2019S mutant LRRK2 PD patients compared to healthy
controls. a Example of control (ctrl) and G2019S mutant LRRK2 PD patient fibroblast stained with pericentrin antibody and DAPI. Scale bar, 10 μm.
b Centrosome phenotype was quantified from 300 cells per line, and from 5 control and 5 G2019S mutant LRRK2 fibroblast lines. Control or
G2019S mutant LRRK2 fibroblasts were treated with LRRK2-IN-1 (500 nM) or GSK2578215A (500 nM) for 60 min. Bars represent mean ± s.e.m.
(between five independent lines). ***, p < 0.005; **, p < 0.01; *, p < 0.05. c Example of control (ctrl) and G2019S mutant LRRK2 PD patient lymphoblast
stained with pericentrin antibody and DAPI. Scale bar, 10 μm. d Centrosome phenotype was quantified from 200 to 300 cells per line, and from three
control and three G2019S mutant LRRK2 lymphoblast lines. Control or G2019S mutant LRRK2 lymphoblasts were treated with MLi2 (10 nM or 100 nM)
or GSK2578215A (500 nM) for 2 h. Bars represent mean ± s.e.m. (between three independent lines). ***, p < 0.005. e Cells were either left untreated or
incubated with 10 nM MLi2 as indicated, and extracts analyzed for phosphorylated (p-S935) or total LRRK2. f Quantification of S935 dephosphorylation
in either control or G2019S-mutant LRRK2 lymphoblasts as indicated, in either the absence or presence of 10 nM MLi2. Bars represent mean ± s.e.m.
(n = 3 lines each); ***, p < 0.005
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to a localization overlapping with that of a centrosomal
marker, indicating that the phosphorylated Rab8a species
preferentially accumulates in a centrosomal compartment
(Fig. 7c and d). Moreover, phosphorylated Rab8a accumu-
lated in a centrosomal compartment irrespective of whether
the cells had duplicated centrosomes or not (Fig. 7c and d),
suggesting that such localization reflects a general feature
not limited to a specific phase of the cell cycle.
We next analyzed whether an increase in centrosomal
phospho-Rab8a may cause the observed alterations in
centrosomal cohesion. Expression of wildtype Rab8a in
wildtype or G2019S mutant LRRK2-expressing SH-SY5Y
Fig. 5 Pathogenic LRRK2 causes kinase-dependent pericentrosomal/centrosomal accumulation of endogenous Rab8a. a, b Examples of non-transfected
HEK293T cells (ctrl) or cells transfected with either wildtype or pathogenic LRRK2, or with kinase-dead pathogenic LRRK2 as indicated, and stained with
γ-tubulin antibody, Rab8a antibody (rabbit polyclonal Rab8a antibody for panel a, sheep polyclonal antibody for panel b), and TOPRO. Scale bar, 5 μm. c
Quantification of the percentage of cells displaying pericentrosomal Rab8a staining in either non-transfected cells (ctrl), or pathogenic LRRK2-transfected
cells as indicated, either in the absence or presence of GSK2578215A (GSK) (500 nM, 1 h). Bars represent mean ± s.e.m., (n = 3 independent experiments);
****, p < 0.001; *, p < 0.05. d Cells were transfected with the indicated constructs, and extracts blotted for GFP-tagged LRRK2, endogenous Rab8a, and
tubulin as loading control. e Cells were either left untreated or incubated with 500 nM GSK2578215A for 1 h as indicated, and extracts analyzed for
phosphorylated (p-S935) or total (GFP) LRRK2. f Quantification of S935 dephosphorylation in cells expressing wildtype or mutant LRRK2 as indicated, in
either the absence or presence of 500 nM GSK2578215A for 1 h. Bars represent mean ± s.e.m. (n = 3); ***, p < 0.005; **, p < 0.01
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cells caused a prominent deficit in centrosomal cohesion
(Fig. 7e and f). Such cohesion deficits were not observed
when expressing the non-phosphorylatable Rab8a-T72A
mutant (Fig. 7e and f), even though both Rab8a variants
were expressed to similar degrees (Fig. 7g). Premature
centrosome splitting induced by G2019S-mutant LRRK2
was not further modulated by the non-phosphorylatable
mutant (Fig. 7f ), indicating that this mutant does not act
as a dominant-negative in this context.
Similar results were obtained in HEK293T cells
(Additional file 7: Figure S7). Co-expression of wildtype
LRRK2 with wildtype Rab8a resulted in LRRK2-mediated
Rab8a phosphorylation, which was further enhanced
when co-expressing the distinct pathogenic, but not
kinase-dead K1906 M or G2019S-K1906 M LRRK2 mu-
tants (Additional file 7: Figure S7a). Co-expression of wild-
type LRRK2 with wildtype Rab8a caused a centrosomal
cohesion deficit which was not observed when expressing
the non-phosphorylatable Rab8a-T72A mutant (Additional
file 7: Figure S7b and c) or when treating cells with kinase
inhibitor (Additional file 7: Figure S7d). Altogether, these
data indicate that increasing the centrosomal amount of
LRRK2-phosphorylated Rab8a correlates with the observed
centrosomal cohesion deficits.
Pathogenic LRRK2-induced centrosomal cohesion and
polarity deficits are mediated by Rab8a
To determine whether the centrosomal deficits caused
by pathogenic LRRK2 kinase were Rab8a-mediated,
HEK293T cells were transiently transfected with small
interfering RNAs (siRNA) directed against a control se-
quence or against Rab8a. Cells transfected with the
Rab8a-specific siRNA showed a significant decrease in
Rab8a protein content when compared to control siRNA
(Fig. 8a and b). Whilst knocking down Rab8a protein
levels did not cause alterations in centrosomal cohesion in
non-transfected cells or in cells transfected with wildtype
LRRK2, it caused a significant reversal in the centrosomal
cohesion deficits induced by pathogenic G2019S, R1441C
or Y1699C LRRK2 expression (Fig. 8c and d).
As an additional means to assure that the observed
reversal of the LRRK2-mediated centrosomal cohesion
deficits were due to knockdown of Rab8a, we generated
siRNA-resistant versions of Rab8a as well as Rab8a-
T72A (Fig. 8e). Whilst siRNA of Rab8a reduced the mu-
tant LRRK2-mediated centrosomal cohesion deficits in
transiently transfected HEK293T cells, those deficits
were restored in the presence of siRNA-resistant Rab8a,
but not of siRNA-resistant Rab8a-T72A mutant (Fig. 8f ).
Therefore, Rab8a, and specifically a phosphorylatable
form of Rab8a, is important for pathogenic LRRK2 to
cause the observed centrosomal deficits.
Finally, when analyzing cell polarization upon scratch
wounding, expression of wildtype Rab8a, but not
phosphorylation-deficient Rab8a, caused a pronounced
decrease in the percentage of cells with reoriented cen-
trosomes in wildtype LRRK2-expressing cells after 4 h
of wounding, whilst not further altering the deficits ob-
served in G2019S LRRK2-expressing cells (Fig. 8g).
Thus, the effects of pathogenic LRRK2 on centrosome
positioning in the context of cell polarity also seem to
involve a Rab8a-mediated phosphorylation event.
Discussion
Here, we provide evidence that mutant LRRK2 causes cen-
trosomal alterations in both dividing and non-dividing cells.
Centrosomal deficits were observed with distinct patho-
genic LRRK2 mutants and in distinct cell lines, as well as
in two different patient-derived cell types. The effects were
reverted by various specific and structurally distinct LRRK2
kinase inhibitors, suggesting that LRRK2 causes centroso-
mal alterations in a kinase activity-dependent manner.
Together, the data indicate that endogenous pathogenic
LRRK2 protein impacts upon the same cellular pathway,
and highlight the potential applicability of such cellular
readout as possible pharmacodynamic assay in clinical
studies employing LRRK2 kinase inhibitors.
Our data confirm that Rab8a is robustly phosphorylated
on T72 by LRRK2 in vitro, and further indicate that phos-
phorylation is largely independent on nucleotide-bound sta-
tus. As compared to wildtype or phosphorylation-deficient
Rab8a, phospho-mimetic Rab8a mutants did not display al-
tered nucleotide binding/dissociation, but were unable to
interact with GDI1/2 or with Rabin8. However, when tran-
siently expressed in cells, the phospho-mimetic Rab8a mu-
tants were not able to mimick the localization or action of
(See figure on previous page.)
Fig. 6 Pathogenic LRRK2 causes kinase-dependent pericentrosomal/centrosomal accumulation of endogenous phospho-Rab8a. a, b Cells were
transfected with pathogenic LRRK2 or with kinase-dead pathogenic LRRK2 as indicated, and stained using an anti-phospho-T72-Rab8a antibody
preabsorbed either with dephospho-peptide (p-Rab8a) or with phospho-peptide (p-Rab8a + pp), or with an anti-phospho-T72-Rab8a antibody
preabsorbed with dephospho-peptide upon incubation of cells with 100 nM MLi2 for 60 min prior to immunocytochemistry as indicated. Scale
bar, 5 μm. c Quantification of the percentage of non-transfected or transfected cells displaying phospho-Rab8a staining colocalizing with centrosomes
within a 3 μm diameter circle in either the absence or presence of antibody preabsorption with peptides or pretreatment of cells with MLi2 as
described above. Around 50 cells were quantified per condition per experiment. Bars represent mean ± s.e.m., (n = 3 independent experiments);
****, p < 0.001. d Quantification of the percentage of non-transfected or transfected cells displaying phospho-Rab8a staining colocalizing with
centrosomes as described above. Around 50 cells were quantified per condition per experiment. Bars represent mean ± s.e.m., (n = 3 independent
experiments); **, p < 0.01
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phosphorylated Rab8a in intact cells. Both the negative
charge and the size of the ionic shell produced by aspartate
or glutamate substitutions are different from those of a
phosphorylated residue at physiological pH. In addition, if
the phosphorylation site serves as a recognition signal
for a binding partner, phospho-mimetic mutants can-
not bind as not fitting into the binding pocket [54, 55].
Therefore, and as observed here, phospho-mimetic muta-
tions often fail to reproduce the changes to a protein
caused by its phosphorylation.
Whilst clearly a LRRK2 kinase substrate, previous studies
have shown that the stoichiometry of Rab8a phosphoryl-
ation in intact cells is low, with the phospho-state-specific
Rab8a antibody only detecting phosphorylated protein by
Fig. 7 Expression of wildtype but not phosphorylation-deficient Rab8a causes centrosomal accumulation of phospho-Rab8a and centrosome cohesion
deficits in wildtype LRRK2-expressing SH-SY5Y cells. a Example of SH-SY5Y cells stably expressing flag-tagged wildtype LRRK2, and transfected with
mRFP-tagged wildtype or T72A-mutant Rab8a as indicated, stained with an anti-phospho-T72-Rab8a antibody preabsorbed with dephosphopeptide,
for pericentrin and DAPI. Where indicated, cells were treated with 100 nM MLi2 for 2 h before immunocytochemistry. Note that phospho-Rab8 can be
detected both in cells with one centrosome (first panel) as well as in cells with duplicated centrosomes (second panel). Scale bar, 10 μm. b Same as in
a, but SH-SY5Y cells stably expressing flag-tagged G2019S mutant LRRK2. Scale bar, 10 μm. c Quantification of mean fluorescence intensity of
phospho-Rab8a signal as described in Methods in cells either stably expressing wildtype (wt) or G2019S mutant LRRK2, transfected with RFP-tagged
Rab8a or T72-mutant Rab8a, and treated with 100 nM MLi2 for 2 h before immunocytochemistry as indicated. Bars represent mean ± s.e.m., (n = 3
independent experiments); ****, p < 0.001; ***, p < 0.005. d Example of non-differentiated SH-SY5Y cells stably expressing GFP, flag-tagged wildtype
or G2019S-mutant LRRK2 as indicated, and transfected with Rab8a or phosphorylation-deficient Rab8a (Rab8a-T72A) as indicated, and stained for
pericentrin and TOPRO. Scare bar, 10 μm. e Quantification of the split centrosome phenotype in SH-SY5Y cells from the type of experiments depicted
in a. Bars represent mean ± s.e.m. (n = 3 experiments); *, p < 0.05. f SH-SY5Y cells stably expressing GFP, flag-tagged wildtype or G2019S-mutant LRRK2
as indicated were transfected with mRFP-tagged wildtype or phosphorylation-deficient Rab8a (Rab8a-T72A) as indicated, and extracts blotted for Rab8a
levels and GAPDH as loading control
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Western blotting techniques upon co-transfection with ex-
ogenous Rab8a [3]. By immunocytochemistry, we could de-
tect accumulation of endogenous phosphorylated Rab8a in
HEK293T cells expressing high levels of exogenous patho-
genic LRRK2, or in SH-SY5Y cells stably expressing LRRK2
upon co-transfection with exogenous Rab8a. In lympho-
blasts which express both high levels of endogenous LRRK2
and of Rab8a, a pericentrosomal/centrosomal phospho-
Rab8a signal was detectable, but there were no statistically
significant differences between G2019S LRRK2 mutant and
control lymphoblasts. These data are consistent with the in-
terpretation that the centrosomal effects mediated by
pathogenic LRRK2 are, at least in part, mediated by Rab8a
and Rab8a phosphorylation, even though currently available
tools do not allow us to detect endogenous phospho-Rab8a
in G2019S mutant lymphoblasts.
The LRRK2-mediated phosphorylation of Rab8a does
not seem to cause a mere loss-of-function phenotype, as
knockdown of Rab8a in control cells did not cause
centrosomal cohesion deficits. Conversely, pathogenic
LRRK2 expression caused centrosomal defects accompan-
ied by an accumulation of endogenous phosphorylated
Rab8a in a pericentrosomal/centrosomal compartment,
and increasing the amount of phosphorylated Rab8a by
coexpression of wildtype LRRK2 with wildtype but not
phospho-deficient Rab8a caused centrosomal cohesion
deficits and centrosomal polarity defects in a kinase
activity-mediated manner as well. Finally, RNAi of Rab8a
in pathogenic LRRK2-expressing cells caused a significant
reversal of centrosomal cohesion deficits. Whilst future
studies will be required to address whether the centroso-
mal cohesion deficits remaining upon Rab8a knockdown
are mediated by remnant Rab8a, by other functionally re-
dundant Rab protein LRRK2 kinase substrates such as
Rab8b or Rab10 [3], or indeed by other, non-Rab-related
LRRK2 substrates, these results indicate that a significant
part of the phenotype is dependent on the presence of
Rab8a. Altogether, our data are consistent with a model
whereby pathogenic LRRK2 kinase activity causes an
abnormal accumulation of phosphorylated Rab8a in a
pericentrosomal/centrosomal compartment with various
downstream effects on centrosome functioning as de-
scribed here.
Centrosomal deficits were also observed in non-
dividing cells. Differentiated SH-SY5Y cells expressing
pathogenic LRRK2 displayed a deficit in cell polarity as
evidenced by a significant increase in the amount of cells
with abnormal positioning of the centrosome with re-
spect to the longest neurite and a decrease in overall dif-
ferentiation capability, consistent with previous reports
that pathogenic LRRK2 interferes with neurite out-
growth [4, 6, 11, 15]. Mutant LRRK2 also caused deficits
in cell polarity associated with an impairment in direc-
tional cell migration. Whilst both positive and negative
effects of mutant LRRK2 on cell migration have been
previously described [12–14], this may relate to cell
type-specific differences in the position of the centro-
some with respect to the leading edge of migratory cells
[56]. In addition, impaired adult neurogenesis in mutant
LRRK2-expressing cells seems to be accompanied by a
reduction in the number of newly generated neurons mi-
grating to the olfactory bulb [15]. As deficits in these
processes may contribute to early clinical signs of PD
such as anosmia, it will be interesting to determine
whether these migrational deficits are due to a lack of
proper centrosome positioning and cell polarization.
Since Rab8a has also been implicated in neurite forma-
tion and polarized membrane transport [57, 58], and
since polarity deficits were also observed when co-
expressing wildtype but not phospho-deficient Rab8a
with wildtype LRRK2, it is tempting to speculate that the
effects on neurite outgrowth and directional migration
may also involve altered Rab8a-mediated processes. Apart
from its abnormal phosphorylation by LRRK2 [3], Rab8a
has also been shown to be phosphorylated by a PINK1-
mediated mechanism [59], and mutations in PINK1 are
known to cause autosomal-recessive PD. In addition,
Rab8a has been shown to modulate α-synuclein-mediated
(See figure on previous page.)
Fig. 8 Knockdown of Rab8a significantly reverses the centrosomal deficits mediated by pathogenic LRRK2. a Representative Western blot of
extracts from control cells (ctrl), or cells transfected with wildtype (wt) or Y1699C-mutant LRRK2, along with either ctrl-siRNA or Rab8a-siRNA as indicated,
and blotted against Rab8a or tubulin as loading control. b Quantification of the type of experiments depicted in a, with levels of Rab8a normalized to
tubulin and to Rab8a levels in the presence of ctrl-siRNA. Bars represent mean ± s.e.m. (n = 3–5 independent experiments); * p < 0.05. c Example of cells
co-transfected with GFP-tagged pathogenic LRRK2 and either ctrl-siRNA or Rab8a-siRNA as indicated, and stained with pericentrin antibody and DAPI.
Scale bar, 10 μm. d Quantification of the split centrosome phenotype in control cells transfected with either ctrl-siRNA or Rab8a-siRNA, or in cells co-
transfected with wildtype or mutant LRRK2 as indicated. Bars represent mean ± s.e.m. (n = 3–5 independent experiments); **** p < 0.001; * p < 0.05. e
Western blot of cell extracts transfected with either ctrl-siRNA or Rab8a-siRNA as indicated, and four hours later cotransfected with mutant LRRK2 and
mRFP-tagged Rab8a, Rab8a-T72A, or siRNA-resistant versions thereof (res), and blotted against Rab8a and GAPDH as loading control. f Quantification of
the split centrosome phenotype in the presence of ctrl-siRNA or Rab8a-siRNA, and in the presence of pathogenic mutant LRRK2 and mRFP-tagged Rab8a,
Rab8a-T72A or siRNA-resistant versions thereof (res) as indicated. Bars represent mean ± s.e.m. (n = 3 independent experiments); *** p < 0.005; ** p < 0.01.
g Quantification of centrosome reorientation in cells stably expressing flag-tagged wildtype or G2019S-mutant LRRK2 together with RFP-tagged wildtype
or phospho-deficient T72A Rab8a 4 h after generating the wound (t = 4 h). Random orientation is expected to be 25%. n > 50 cells were quantified for
each condition in each experiment. Bars represent mean ± s.e.m. (n = 3 independent experiments); **, p < 0.01; *, p < 0.05
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aggregation and toxicity in cellular and animal models of
PD [60]. Thus, whilst the precise mechanism(s) remain to
be further determined, there is increasing evidence linking
abnormal Rab8a function with PD pathogenesis.
The link between centrosomal alterations as described
here and its relevance to PD remains unclear. Deficits in
adult neurogenesis have been reported to contribute to
the age-dependent non-motor symptoms of PD patients
[17, 18], and it will be interesting to determine whether
alterations in centrosomal cohesion parallel the deficits
in cell growth of neuronal precursor cells derived from
LRRK2 PD patients in vitro, or the impairment of adult
neurogenesis in mutant LRRK2-transgenic mice in vivo
[15, 16]. In addition, as centrosomal alterations are fre-
quently associated with cancer, the changes reported here
may further contribute to the reported increased cancer
risk in LRRK2 PD patients [61]. Importantly, centrosomes
are the major microtubule-nucleating centers within a cell,
and proper centrosome functioning and orientation ensure
appropriate microtubule-mediated vesicular trafficking.
Interestingly, pathogenic LRRK2 has been linked to
alterations in microtubule stability [62] and to intracellular
vesicular trafficking steps including the autophagy, endoly-
sosomal and retromer-mediated trafficking pathways
[4–9, 19, 63]. Therefore, the centrosomal alterations de-
scribed here may contribute to the observed alterations in
microtubule-mediated membrane trafficking pathways
which have been directly related to the pathobiology
of PD [64, 65].
In summary, we here provide evidence that pathogenic
LRRK2 causes deficits in centrosome positioning and co-
hesion in a manner dependent on kinase activity and
Rab8a phosphorylation. Our findings hopefully provide a
useful framework for future studies aimed at determin-
ing the relative contribution of centrosomal deficits to
the various cellular alterations described to be relevant
in the context of PD pathogenesis and amenable to
LRRK2 kinase inhibitor-mediated strategies.
Conclusions
Our data indicate that pathogenic LRRK2 causes centroso-
mal polarity and cohesion deficits. Such centrosomal de-
fects have impacts on neurite outgrowth, cell polarization
and migration. These defects are LRRK2 kinase activity-
mediated, and are also observed in patient-derived cells.
The centrosomal deficits in both dividing and non-dividing
cells are largely due to LRRK2-mediated Rab8a phosphor-
ylation. Thus, our study reveals a novel role for pathogenic
LRRK2 related to proper centrosome functioning, which
may not only contribute to neurodegeneration, but
may also account for some early manifestations of the
disease and the increased incidence of cancer seen in
PD patients.
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